NASDAQ:CNMD - CONMED Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $74.84 +1.12 (+1.52 %) (As of 02/21/2019 02:55 PM ET)Previous Close$73.72Today's Range$73.65 - $75.0852-Week Range$56.90 - $83.49Volume3,998 shsAverage Volume401,938 shsMarket Capitalization$2.11 billionP/E Ratio34.41Dividend Yield1.07%Beta0.68 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company's products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York. Receive CNMD News and Ratings via Email Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:CNMD Previous Symbol CUSIP20741010 Webwww.conmed.com Phone315-797-8375Debt Debt-to-Equity Ratio0.68 Current Ratio2.20 Quick Ratio1.27Price-To-Earnings Trailing P/E Ratio34.41 Forward P/E Ratio30.67 P/E Growth2.66 Sales & Book Value Annual Sales$859.63 million Price / Sales2.45 Cash Flow$4.0086 per share Price / Cash Flow18.67 Book Value$22.60 per share Price / Book3.31Profitability EPS (Most Recent Fiscal Year)$2.18 Net Income$40.85 million Net Margins4.75% Return on Equity9.70% Return on Assets4.62%Miscellaneous Employees3,100 Outstanding Shares28,130,000Market Cap$2.11 billion OptionableOptionable CONMED (NASDAQ:CNMD) Frequently Asked Questions What is CONMED's stock symbol? CONMED trades on the NASDAQ under the ticker symbol "CNMD." How often does CONMED pay dividends? What is the dividend yield for CONMED? CONMED announced a quarterly dividend on Friday, November 9th. Investors of record on Friday, December 14th will be paid a dividend of $0.20 per share on Monday, January 7th. This represents a $0.80 annualized dividend and a yield of 1.07%. The ex-dividend date of this dividend is Thursday, December 13th. View CONMED's Dividend History. How were CONMED's earnings last quarter? CONMED Co. (NASDAQ:CNMD) released its quarterly earnings results on Tuesday, January, 22nd. The medical technology company reported $0.73 EPS for the quarter, meeting analysts' consensus estimates of $0.73. The medical technology company earned $242.40 million during the quarter, compared to analyst estimates of $228.40 million. CONMED had a net margin of 4.75% and a return on equity of 9.70%. CONMED's quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.69 earnings per share. View CONMED's Earnings History. When is CONMED's next earnings date? CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for CONMED. What guidance has CONMED issued on next quarter's earnings? CONMED updated its FY19 earnings guidance on Tuesday, January, 22nd. The company provided earnings per share (EPS) guidance of $2.42-$2.47 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.42. The company issued revenue guidance of $902.6-$911.8 million, compared to the consensus revenue estimate of $889.37 million.CONMED also updated its FY 2019 guidance to $2.42-2.47 EPS. What price target have analysts set for CNMD? 3 analysts have issued 1-year price targets for CONMED's shares. Their forecasts range from $79.00 to $85.00. On average, they anticipate CONMED's stock price to reach $81.6667 in the next year. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Price Targets for CONMED. What is the consensus analysts' recommendation for CONMED? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CONMED. What are Wall Street analysts saying about CONMED stock? Here are some recent quotes from research analysts about CONMED stock: 1. According to Zacks Investment Research, "CONMED exited the fourth quarter on a solid note, with earnings and revenues beating estimates. The company’s core units — Orthopedic Surgery and General Surgery — continue to boost the topline. Of the most unique products under General Surgery, the Anchor Tissue Retrieval bag deserves a mention. Solid international sales growth is a positive. Management is confident of the product portfolio as well. It expects the ongoing buyout of Buffalo Filter to boost CONMED’s General Surgery portfolio. A strong 2019 guidance buoy optimism in the stock. Reflective of these, CONMED has outperformed the industry in a year’s time. On the flip side, contraction in the company's gross and operating margins in the quarter is worrisome. CONMED operates in a highly competitive environment, especially with respect to the General Surgery business. The company’s high long-term debt is a concern." (1/25/2019) 2. Needham & Company LLC analysts commented, "CNMD’s 4Q18 revenue beat consensus while its EPS was in line with consensus. Management provided 2019 revenue and EPS guidance that were both above consensus. Revenue growth improved to 10.8% CC (or ~9.3% CC after adjusting for an extra selling day) in 4Q18 from 8.1% CC in 3Q18 despite a more difficult comp. CNMD’s revenue grew 8.4% in 2018, which is ~400 bps above the mid-point of its original 4-5% guidance. We believe that the 2019 revenue guidance is similarly conservative and note that management indicated that they intend to allow any revenue upside to fall through to the bottom line rather than reinvesting this as in 2018. Given this, we reiterate our Buy rating." (1/23/2019) Has CONMED been receiving favorable news coverage? News articles about CNMD stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CONMED earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned news articles about the medical technology company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of CONMED's key competitors? Some companies that are related to CONMED include Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), NxStage Medical (NXTM), Natus Medical (BABY), Viewray (VRAY), AxoGen (AXGN), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Cutera (CUTR), Electrocore (ECOR), Helius Medical Technologies (HSDT), Zynex (ZYXI) and Fonar (FONR). What other stocks do shareholders of CONMED own? Based on aggregate information from My MarketBeat watchlists, some companies that other CONMED investors own include Gilead Sciences (GILD), Exelixis (EXEL), Fate Therapeutics (FATE), The Medicines (MDCO), Spectrum Pharmaceuticals (SPPI), Galmed Pharmaceuticals (GLMD), Galectin Therapeutics (GALT), PRA Health Sciences (PRAH), Incyte (INCY) and Fonar (FONR). Who are CONMED's key executives? CONMED's management team includes the folowing people: Mr. Curt R. Hartman, CEO, Pres & Director (Age 55)Mr. Patrick J. Beyer, Pres of CONMED International (Age 53)Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 44)Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 44)Mr. Todd W. Garner, Exec. VP & CFO (Age 50) Who are CONMED's major shareholders? CONMED's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.19%), Dimensional Fund Advisors LP (5.83%), Macquarie Group Ltd. (2.87%), Northern Trust Corp (2.15%), Fisher Asset Management LLC (2.06%) and Victory Capital Management Inc. (1.89%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED. Which institutional investors are selling CONMED stock? CNMD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Dimensional Fund Advisors LP, Gotham Asset Management LLC, United Services Automobile Association, Bank of New York Mellon Corp, First Trust Advisors LP, Barclays PLC and GSA Capital Partners LLP. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED. Which institutional investors are buying CONMED stock? CNMD stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Hsbc Holdings PLC, 361 Capital LLC, Geode Capital Management LLC, Virginia Retirement Systems ET AL, Two Sigma Investments LP and Squarepoint Ops LLC. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED. How do I buy shares of CONMED? Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CONMED's stock price today? One share of CNMD stock can currently be purchased for approximately $74.98. How big of a company is CONMED? CONMED has a market capitalization of $2.11 billion and generates $859.63 million in revenue each year. The medical technology company earns $40.85 million in net income (profit) each year or $2.18 on an earnings per share basis. CONMED employs 3,100 workers across the globe. What is CONMED's official website? The official website for CONMED is http://www.conmed.com. How can I contact CONMED? CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375. MarketBeat Community Rating for CONMED (NASDAQ CNMD)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 314 (Vote Outperform)Underperform Votes: 248 (Vote Underperform)Total Votes: 562MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: What is the NASDAQ?